Exploring the Profiles of ROS1 Tyrosine Kinase: A Structural Analysis of G2032R and D2033N Mutations

Syed Ikramul Hasan1

  • 1Department of Basic Medical Science, College of Applied Medical Sciences, Al-Baha University, Al Bahah, Saudi Arabia.

Abstract

Insights

The G2032R and D2033N mutations in ROS1 destabilize its structure, impacting protein dynamics and contributing to cancer development. These findings offer insights into resistance mechanisms against crizotinib treatment.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Oncology

Background:

  • ROS1 proto-oncogene fusions drive cancer, particularly non-small cell lung cancer.
  • Specific mutations (G2032R, D2033N) in ROS1 confer resistance to crizotinib therapy.
  • Understanding these mutations' structural impact is crucial for developing effective cancer treatments.

Purpose of the Study:

  • To investigate the structural consequences of G2032R and D2033N mutations in ROS1.
  • To elucidate how these mutations affect ROS1 protein stability and dynamics.
  • To provide insights into the molecular mechanisms underlying crizotinib resistance in ROS1-rearranged cancers.

Main Methods:

  • Homology modeling based on the human ROS1 crystal structure (PDB ID: 7z5x).
  • Introduction of G2032R and D2033N mutations using Swiss-PdbViewer.
  • Molecular dynamics (MD) simulations of wild-type (WT) and mutant ROS1 kinase domains over 500 ns.

Main Results:

  • MD simulations revealed significant conformational changes in the G2032R and D2033N ROS1 mutants.
  • Mutations induced deviations in the MD trajectory, indicating altered protein dynamics.
  • Destabilization was observed, particularly affecting the ATP binding and active sites of ROS1.

Conclusions:

  • The G2032R and D2033N mutations substantially alter ROS1 structure, stability, and dynamics.
  • These structural changes provide a molecular basis for crizotinib resistance.
  • The findings enhance understanding of ROS1-driven cancer development and therapeutic resistance.